Home > Haematology > Double-targeted CAR-T cell immunotherapy promising for refractory non-Hodgkin lymphoma

Double-targeted CAR-T cell immunotherapy promising for refractory non-Hodgkin lymphoma


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138

Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
Journal
Nature Medicine
Reuters Health - 14/10/2020 - A novel chimeric antigen receptor (CAR)-T cell therapy for refractory B-cell non-Hodgkin lymphoma that targets both CD19 and CD20 antigens was safe and potentially effective in a feasibility study, setting the stage for a multicenter phase-2 trial, researchers say. "We hope that this dual-targeted CAR-T will lead to better outcomes with less toxicity for patients with relapsed, refractory aggressive non-Hodgkin lymphoma," Dr. Nirav Shah of Medical College of Wisconsin in Milwaukee told Reuters Health by email. "We also hope that the rapid manufacturing will allow patients to get CAR-T cells in an expedited fashion." "Our phase-1 study has demonstrated safety and a promising response profile," he noted. "However, larger studies are indicated to confirm this efficacy signal, and we hope to do that in the planned phase-2 trial. We hope to launch in the first quarter of 2021 and expect the study to last one year." As reported in Natu...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on